SCHEMBL266759

SCHEMBL266759

COc1ccc(C(=O)Nc2ccc(C)cc2C(=O)N/N=C/c2cccc(C)c2)cc1OC

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.63
NPC1 O15118 2/20 0.63
PKM P14618 2/20 0.63
KDM4E B2RXH2 4/20 0.59
HTT P42858 2/20 0.59
TDP1 Q9NUW8 2/20 0.59
OPRK1 P41145 1/20 0.59
SMN1; SMN2 Q16637 4/20 0.53
ALDH1A1 P00352 3/20 0.53
GAA P10253 1/20 0.53
MAPT P10636 6/20 0.52
MEN1 O00255 2/20 0.52
KMT2A Q03164 2/20 0.52
ALOX12 P18054 2/20 0.52
HPGD P15428 1/20 0.52
NPSR1 Q6W5P4 1/20 0.52
POLB P06746 1/20 0.50
CHEK1 O14757 1/20 0.50
PIM1 P11309 1/20 0.50
MAPK8 P45983 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL266760 1.00 RAB9A (0.63) RAB9ANPC1PKMKDM4EHTT
SCHEMBL265407 0.93 RAB9A (0.60) RAB9ANPC1PKMKDM4EHTT
SCHEMBL269254 0.93 NPC1 (0.60) RAB9ANPC1PKMKDM4EHTT
SCHEMBL269255 0.93 NPC1 (0.60) RAB9ANPC1PKMKDM4EHTT
SCHEMBL265408 0.93 RAB9A (0.60) RAB9ANPC1PKMKDM4EHTT
SCHEMBL268616 0.93 RAB9A (0.59) RAB9ANPC1PKMKDM4EHTT
SCHEMBL268617 0.93 RAB9A (0.59) RAB9ANPC1PKMKDM4EHTT
SCHEMBL269541 0.93 RAB9A (0.59) RAB9ANPC1PKMKDM4EHTT
SCHEMBL269542 0.93 RAB9A (0.59) RAB9ANPC1PKMKDM4EHTT
SCHEMBL266901 0.93 RAB9A (0.59) RAB9ANPC1PKMKDM4EHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same KIRIN BEER KABUSHIKI KAISHA (JP) 2006-09-28 US disclosed
EP-1614676-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KIRIN BEER KABUSHIKI KAISHA (JP) 2006-01-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same SLC10A6, SLC7A1, SLC10A1 RAB9A 883/4885NPC1 102/4885PKM 1697/4885
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME SLC34A1, SLC34A2, SLC20A2 RAB9A 1362/4885NPC1 115/4885PKM 1916/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.